UNDERWRITING AGREEMENT between MARPAI, INC. and THINKEQUITY LLC as Representative of the Several UnderwritersUnderwriting Agreement • October 6th, 2023 • Marpai, Inc. • Services-misc health & allied services, nec • New York
Contract Type FiledOctober 6th, 2023 Company Industry Jurisdiction
UNDERWRITING AGREEMENT between CYTOMED THERAPEUTICS LIMITED and THE BENCHMARK COMPANY, LLC as Representative of the Several Underwriters CYTOMED THERAPEUTICS LIMITEDUnderwriting Agreement • April 18th, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations • New York
Contract Type FiledApril 18th, 2023 Company Industry JurisdictionThe undersigned, CytoMed Therapeutics Limited, a public company limited by shares pursuant to the provisions of the Singapore Companies Act formed under the laws of the Republic of Singapore (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of CytoMed Therapeutics Limited, the “Company”), hereby confirms its agreement (this “Agreement”) with The Benchmark Company, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
UNDERWRITING AGREEMENT between PYXIS TANKERS INC. and THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., as Representative of the Several UnderwritersUnderwriting Agreement • October 13th, 2020 • Pyxis Tankers Inc. • Deep sea foreign transportation of freight • New York
Contract Type FiledOctober 13th, 2020 Company Industry JurisdictionA Division of Fordham Financial Management, Inc. As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 22nd Floor New York, New York 10004
UNDERWRITING AGREEMENT between FAT BRANDS INC. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters FAT BRANDS INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 10th, 2020 • Fat Brands, Inc • Retail-eating places • New York
Contract Type FiledJuly 10th, 2020 Company Industry JurisdictionThe undersigned, FAT Brands Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of FAT Brands Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
PolarityTE, Inc. 10,638,298 Shares of Common Stock (par value $0.001 per share) Warrants to Purchase 10,638,298 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 14th, 2020 • Polarityte, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 14th, 2020 Company Industry JurisdictionPolarityTE, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 10,638,298 shares (the “Offered Shares”) of its common stock, par value $0.001 per share (the “Shares”), and (ii) warrants to purchase an aggregate of 10,638,298 Shares (the “Warrants”) in the form attached as Exhibit A.
par value $0.0001 and Warrants to Purchase 10,750,000 Shares of Common Stock REXAHN PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • January 25th, 2019 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 25th, 2019 Company Industry JurisdictionRexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) 10,750,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and (ii) warrants to purchase up to an aggregate of 10,750,000 shares of Common Stock (the “Warrants”). The respective amounts of the Shares and Warrants to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. The aggregate number of shares of Common Stock issuable upon exercise of the Warrants is hereinafter referred to as the “Warrant Shares.” The Shares, Warrants and Warrant Shares are collectively called the “Securities.”
UNDERWRITING AGREEMENT between TOWERSTREAM CORPORATION and JOSEPH GUNNAR & CO., LLC as Representative of the Several UnderwritersUnderwriting Agreement • October 19th, 2017 • Towerstream Corp • Communications services, nec • New York
Contract Type FiledOctober 19th, 2017 Company Industry JurisdictionJoseph Gunnar & Co., LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 30 Broad Street, 11th Fl
and Warrants to Purchase 2,484,789 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 30th, 2016 • ContraVir Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 30th, 2016 Company Industry JurisdictionContraVir Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the public through Laidlaw & Company (UK) Ltd, as representative (the “Representative”) of the several underwriters (the “Underwriters”) named in Schedule I hereto, on a best efforts basis, (i) up to an aggregate of 4,929,578 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company and (ii) five-year warrants to purchase shares of Common Stock at an exercise price of $1.70 per share, or warrants to purchase up to an aggregate of 2,484,789 shares of Common Stock (the “Warrants” and the shares of Common Stock underlying the Warrants, the “Warrant Shares”). The Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities.” The Shares and the Warrants shall be immediately separable and transferable upon issuance. The terms of the Warrants are set forth in the f
and Warrants to Purchase 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 7th, 2015 • ContraVir Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 7th, 2015 Company Industry JurisdictionContraVir Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Laidlaw & Company (UK) Ltd. is acting as representative (the “Representative”), (i) an aggregate of 5,000,000 shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company and (ii) five-year warrants to purchase shares of Common Stock at an exercise price of $4.25 per share, or warrants to purchase an aggregate of 3,000,000 shares of Common Stock (the “Firm Warrants” and the shares of Common Stock underlying the Firm Warrants, the “Firm Warrant Shares”). The Company has granted the Underwriters the option to purchase an aggregate of up to an additional (a) 750,000 shares (the “Option Shares”) of Common Stock and (b) five-year warrants (the “Optional Warrants”) to purchase up to an aggrega